Clene Inc. (CLNN)
Largest Insider Buys in Sector
CLNN Stock Price History Chart
CLNN Stock Performance
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy …
Insider Activity of Clene Inc.
Over the last 12 months, insiders at Clene Inc. have bought $583,390 and sold $22,516 worth of Clene Inc. stock.
On average, over the past 5 years, insiders at Clene Inc. have bought $6.12M and sold $796,474 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MATLIN DAVID J (director) — $876,917. Mortenson Mark (Chief Science Officer) — $97,432. Etherington Robert Dee (Chief Executive Officer) — $47,500.
The last purchase of 92,307 shares for transaction amount of $438,458 was made by MATLIN DAVID J (director) on 2024‑09‑30.
List of Insider Buy and Sell Transactions, Clene Inc.
| 2024-09-30 | director | 92,307 1.4829% | $4.75 | $438,458 | +21.24% | |||
| 2024-09-30 | Chief Executive Officer | 10,000 0.1606% | $4.75 | $47,500 | +21.24% | |||
| 2024-09-30 | Chief Science Officer | 20,512 0.3295% | $4.75 | $97,432 | +21.24% | |||
| 2024-05-01 | Sale | 10 percent owner | 13,000 0.0092% | $0.40 | $5,148 | -33.81% | ||
| 2024-04-30 | Sale | 10 percent owner | 13,000 0.0098% | $0.42 | $5,416 | -32.64% | ||
| 2024-04-24 | Sale | 10 percent owner | 10,000 0.0076% | $0.33 | $3,278 | -13.20% | ||
| 2024-04-09 | Sale | 10 percent owner | 22,500 0.0172% | $0.39 | $8,675 | -21.49% | ||
| 2023-11-10 | director | 250,002 0.1815% | $0.41 | $102,501 | -17.56% | |||
| 2023-06-26 | director | 316,455 0.4161% | $0.80 | $253,164 | -45.16% | |||
| 2023-06-26 | Chief Executive Officer | 25,000 0.0333% | $0.81 | $20,250 | -45.16% | |||
| 2023-06-16 | 10 percent owner | 7.5M 9.259% | $0.80 | $6M | -47.83% | |||
| 2023-06-16 | director | 1.5M 1.8518% | $0.80 | $1.2M | -47.83% | |||
| 2023-06-16 | director | 2.39M 2.9559% | $0.80 | $1.92M | -47.83% | |||
| 2023-06-16 | director | 105,625 0.1304% | $0.80 | $84,500 | -47.83% | |||
| 2022-11-02 | director | 990,099 1.4746% | $1.01 | $1,000,000 | -7.69% | |||
| 2022-11-02 | director | 2.87M 4.2765% | $1.01 | $2.9M | -7.69% | |||
| 2022-11-02 | director | 990,099 1.4746% | $1.01 | $1,000,000 | -7.69% | |||
| 2022-11-02 | director | 792,079 1.1797% | $1.01 | $800,000 | -7.69% | |||
| 2022-11-02 | director | 148,515 0.2212% | $1.01 | $150,000 | -7.69% | |||
| 2022-08-17 | 47,662 0.0756% | $3.85 | $183,499 | -72.25% |
Insider Historical Profitability
| MATLIN DAVID J | director | 444491 5.5703% | $4.01 | 22 | 0 | <0.0001% |
| Etherington Robert Dee | Chief Executive Officer | 40149 0.5031% | $4.01 | 2 | 1 | <0.0001% |
| Mortenson Mark | Chief Science Officer | 28949 0.3628% | $4.01 | 1 | 1 | |
| Ugwumba Chidozie | 10 percent owner | 13018908 163.1497% | $4.01 | 2 | 0 | <0.0001% |
| Mosca Alison | director | 3238375 40.5825% | $4.01 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $1.11B | 40.8 | 2.62M | +0.05% | +$559,401.17 | 0.02 | |
| Geode Capital Management | $402.76M | 14.74 | 946,532 | +54.69% | +$142.4M | 0.03 | |
| Scoggin Management Lp | $212.7M | 7.79 | 500,000 | -33.33% | -$106.35M | 61.37 | |
| Alyeska Investment Group L P | $201.69M | 7.38 | 474,130 | -71.89% | -$515.91M | 1.24 | |
| Morgan Stanley | $144.06M | 5.27 | 338,635 | 0% | +$0 | 0.01 |